Conveners
Clinical Session
- Jos Malda (UMC Utrecht)
The true need for transplantable organs has been estimated to be in the order of few millions only in the Western world.
As, worldwide, only 172,397 transplants were performed in 2024, we can infer that the current approach to organ transplantation is inadequate.
The idea of replacing a terminally diseased organs with a new, functional one procured from another individual dates to more than...
Translating biotherapeutics into clinical practice is essential for enhancing patients' quality of life and reducing therapy costs, ultimately democratizing access to treatments for all. This overview highlights the Mayo Clinic Center for Regenerative Biotherapeutics, dedicated to clinical translation of novel therapies into early-phase clinical trials. With facilities in Minnesota, Florida,...
3D bioprinting is emerging as one of the most disruptive technologies in modern medicine, offering the possibility to fabricate patient-specific tissues and organs for regenerative therapies, disease modelling, and drug testing. However, its translation from laboratory research to clinical application faces significant scientific, manufacturing, and regulatory challenges—particularly within...
We developed the Kenzan Method, a scaffold-free, 3D Biofabrication system that uses multicellular spheroids as building blocks. These spheroids are temporarily pierced on a needle array (“KenZan”), where they fuse, self-organize and secrete their own extracellular matrix, yielding purely cellular, functional tissue constructs without foreign materials.
We have demonstrated its versatility...
The recent emergence of additive manufacturing/ 3D printing offers novel routes to fabricate implants and tissue scaffolds of complex architecture, which are personalized to meet the patient’s needs. In this talk, I will highlight some key ongoing efforts in our group on developing advanced biomaterials and biofabrication strategies to meet clinical needs. These efforts span a variety of...
